Latest Breaking News On - Shanghai junshi biosciences co ltd - Page 1 : comparemela.com

Junshi Biosciences Announces NDA Acceptance in Hong Kong

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading.

Maryland
United-states
United-kingdom
Beijing
China
San-francisco
California
Suzhou
Jiangsu
Singapore
Malaysia
Hong-kong-special-administrative-region

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

India
Malaysia
Suzhou
Jiangsu
China
Beijing
Singapore
Jordan
Australia
Hong-kong-special-administrative-region
Hong-kong-general
Hong-kong

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

China
Peking
Beijing
Jun-guo
National-medical-products-administration-of-china
Shanghai-junshi-biosciences-co-ltd
University-cancer-hospital
International-metastatic-renal-cell-carcinoma-database-consortium
National-medical-products-administration
Peking-university-cancer-hospital
News
Global-oncology

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer By Investing.com

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer By Investing.com
investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.

United-states
Beijing
China
Australia
Renji
Henan
Peking
Guangzhou
Guangdong
Shanghai
Singapore
San-francisco

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Australia
Singapore
Maryland
United-states
Shanghai
China
Suzhou
Jiangsu
Peking
Beijing
Guangzhou
Guangdong